CONMED Corporation (CNMD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 862 | 1,011 | 1,045 | 1,245 | 1,307 | 1,374 | 1,373 | 1,366 |
| Operating profit | $m | 141 | 148 | ||||||
| Net profit | $m | 10 | 63 | -81 | 64 | 132 | 47 | 56 | 141 |
| EPS reported | $ | 1.51 | 1.85 | ||||||
| Operating cashflow per share | $ | 5.50 | 5.01 | ||||||
| Capex per share | $ | 0.64 | 0.54 | ||||||
| FCF per share | $ | 4.86 | 4.47 | ||||||
| Free cash flow | $m | 151 | 134 | ||||||
| Net debt | $m | 794 | 797 | ||||||
| Book value equity | $m | 1,033 | 1,041 | ||||||
| Book value per share | $ | 33.17 | 34.58 | ||||||
| Number of shares | m | 31.15 | 30.12 | ||||||
| DPS (TTM paid) | $ | 0.60 | 0.41 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 26.89 | 24.50 | ||||||
| P/B LTM | x | 1.22 | 1.21 | ||||||
| P/S LTM | x | 0.92 | 0.92 | ||||||
| P/FCF LTM | x | 8.35 | 9.37 | ||||||
| EV/EBITDA LTM | x | 13.29 | 11.41 | ||||||
| EV/Sales LTM | x | 1.49 | 1.66 | ||||||
| Earnings Yield LTM | % | +3.72% | +4.08% | ||||||
| FCF Yield | % | +11.97% | +10.67% | ||||||
| Quality | |||||||||
| ROE | % | +4.55% | +5.51% | ||||||
| ROIC | % | +4.64% | +4.97% | ||||||
| Operating margin | % | +10.27% | +10.79% | ||||||
| Gross margin | % | +52.77% | +54.80% | ||||||
| FCF/Sales | % | +10.98% | +9.80% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -64.55% | -56.57% | ||||||
| Sales Growth YoY | % | +5.16% | +5.02% | ||||||
| Net Income Growth YoY | % | -64.47% | -57.34% | ||||||
| FCF Growth | % | -1.95% | -12.62% | ||||||
| Operating Profit Growth | % | -29.55% | -26.07% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +1.96% | +0.41% | ||||||
| Dividend Growth | % | -25.00% | -48.62% | ||||||
| Payout Ratio | % | +52.61% | +21.77% | ||||||
| FCF/Debt | x | 0.18 | 0.16 | ||||||
| Net Debt/EBITDA | x | 5.14 | 4.43 | ||||||
| EBIT/Net interest | x | 4.54 | 4.95 | ||||||
| Net debt/market cap | % | +66.26% | +56.48% | ||||||
| Net debt/Equity | x | 0.77 | 0.77 | ||||||
| Gross debt/equity | x | 0.81 | 0.80 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free